Related content

Development of NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor

By Kimura Shinya   Niwa Tomoko   Hirabayashi Kazuko   Maekawa Taira  

Cancer Chemotherapy and Pharmacology, Vol. 58, Iss. 7, 2006-11 ,pp. : 55-61

Springer Publishing Company

Access to resources Recommend Favorite

Switching to second‐generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib‐treated patients with chronic myeloid leukemia with more than 10% of BCR‐ABL/ABL ratio at 3 months

By  

Cancer Medicine, Vol. 4, Iss. 7, 2015-07 ,pp. : 995-1002

John Wiley & Sons Inc

Access to resources Recommend Favorite

Abl tyrosine protein kinase

By Laneuville P.  

Seminars in Immunology, Vol. 7, Iss. 4, 1995-04 ,pp. : 255-266

Academic Press

Access to resources Recommend Favorite

Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor

By Patrawala Samit   Puzanov Igor  

Future Oncology, Vol. 8, Iss. 5, 2012-05 ,pp. : 509-523

Future Medicine

Access to resources Recommend Favorite

Second Generation Abl Kinase Inhibitors and Novel Compounds to Eliminate the Bcr-Abl/T315I Clone

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 1, Iss. 3, 2006-11 ,pp. : 347-355

Bentham Science Publishers

Access to resources Recommend Favorite